Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Total Liabilities (2020 - 2025)

Historic Total Liabilities for Inhibikase Therapeutics (IKT) over the last 6 years, with Q3 2025 value amounting to $6.7 million.

  • Inhibikase Therapeutics' Total Liabilities rose 3645.01% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 million, marking a year-over-year increase of 3645.01%. This contributed to the annual value of $3.7 million for FY2024, which is 580.5% up from last year.
  • Inhibikase Therapeutics' Total Liabilities amounted to $6.7 million in Q3 2025, which was up 3645.01% from $8.8 million recorded in Q2 2025.
  • Inhibikase Therapeutics' 5-year Total Liabilities high stood at $8.8 million for Q2 2025, and its period low was $2.2 million during Q2 2021.
  • Its 5-year average for Total Liabilities is $4.3 million, with a median of $3.8 million in 2021.
  • Its Total Liabilities has fluctuated over the past 5 years, first tumbled by 5525.37% in 2021, then skyrocketed by 13590.33% in 2025.
  • Quarter analysis of 5 years shows Inhibikase Therapeutics' Total Liabilities stood at $4.1 million in 2021, then fell by 3.79% to $3.9 million in 2022, then dropped by 9.54% to $3.5 million in 2023, then grew by 5.8% to $3.7 million in 2024, then skyrocketed by 79.35% to $6.7 million in 2025.
  • Its last three reported values are $6.7 million in Q3 2025, $8.8 million for Q2 2025, and $8.6 million during Q1 2025.